Art. -Nr.: HY-123037

Triadimefon

Kundenbewertung

Based on 1 Customer Validation

Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.12%
CAS. Nr.: 43121-43-3
Formel: C₁₄H₁₆ClN₃O₂
Molecular Weight:293.75

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Triadimefon Chemical Structure

CAS. Nr.: 43121-43-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[2]

Akt1

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle AMPK Isoform-spezifische Produkte anzeigen :

In Vitro

Triadimefon (5-50 mg/L) significantly inhibits the growth of Saccharomyces cerevisiae (45%-100% inhibition)^[1].
Triadimefon (0.15-0.3 mM; 3 days) significantly reduces albumin production in primary rat hepatocytes and induces a metabolic shift in hepatocytes (from glycolysis to gluconeogenesis and from fatty acid synthesis to fatty acid oxidation)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Saccharomyces cerevisiae CICC 1202
Concentration:

0.1 mg/L, 1.0 mg/L, 5.0 mg/L, 10 mg/L, 50 mg/L
Incubation Time:
Result:

Did not significantly affect yeast growth at 0.1 mg/L and 1.0 mg/L.
Significantly reduced cell viability, with 45%, 80%, and 100% growth inhibition at 5 mg/L, 10 mg/L, and 50 mg/L, respectively.

In Vivo

Triadimefon (25-100 mg/kg; p.o.; daily; 10 days (from gestational day 12 to 21)) inhibits fetal adrenal development in rats^[2].
Triadimefon (25-100 mg/kg; p.o.; 9 days (GD 12-GD 20)) significantly reduces serum testosterone level, increases the number of fetal Leydig cells with abnormal aggregation in male fetuses, downregulates testis-related gene and protein expression, induces oxidative stress in pregnant Sprague-Dawley rats^[5].
Triadimefon (20-200 mg/kg; i.p.; once daily; 7 consecutive days) significantly inhibits spatial learning ability, impairs spatial reference memory, and reduces hippocampal retinoic acid (HY-14649) concentration in rats^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Pregnant Sprague-Dawley rats and their male fetuses^[2]
Dosage:

0 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg
Administration:

Gavage (2 mL/kg); daily; from gestational day (GD) 12 to GD 21 (10 days)
Result:

Significantly reduced the thickness of zona fasciculata and serum aldosterone level in male fetuses.
Reduced serum corticosterone and ACTH levels.
Showed downregulation of Agtr1, Mc2r, Star, Cyp11b1, Cyp11b2, Igf1, Nr5a1, Sod2, Gpx1, and Cat mRNA.
Reduced AT1R, CYP11B2, IGF1, NR5A1, and MC2R protein levels.
Significantly reduced phosphorylation of AKT1 and ERK1/2.
Significantly increased pAMPK level without affecting total AMPK.

Chemical Information

CAS. Nr. 43121-43-3
Appearance Solid
Molecular Weight 293.75
Formel C₁₄H₁₆ClN₃O₂
Color White to off-white
SMILES

CC(C)(C(C(N1N=CN=C1)OC2=CC=C(C=C2)Cl)=O)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (851.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4043 mL

17.0213 mL

34.0426 mL

5 mM

0.6809 mL

3.4043 mL

6.8085 mL

10 mM

0.3404 mL

1.7021 mL

3.4043 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (7.08 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (624 KB)
- English - EN (624 KB)
- Français - FR (624 KB)
- Deutsch - DE (624 KB)
- Norwegian - NO (624 KB)
- Español - ES (624 KB)
- Swedish - SV (624 KB)
- Italian - IT (624 KB)
- Korean - KR (624 KB)
- Portuguese - PT (624 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kong Z, et al. The fungicide triadimefon affects beer flavor and composition by influencing Saccharomyces cerevisiae metabolism. Sci Rep. 2016 Sep 15;6:33552. [Content Brief]

[2]. Xu Q, et al. Triadimefon suppresses fetal adrenal gland development after in utero exposure. Toxicology. 2021 Oct;462:152932. [Content Brief]

[3]. Iyer V V, et al. Effects of Triadimefon on the Metabolism of Cultured Hepatocytes[C]//2010 IEEE International Conference on BioInformatics and BioEngineering. IEEE, 2010: 118-123.

[4]. Walker QD, et al. Triadimefon and triadimenol: effects on monoamine uptake and release. Toxicol Appl Pharmacol. 1996 Aug;139(2):227-33. [Content Brief]

[5]. Lin L, et al. Triadimefon increases fetal Leydig cell proliferation but inhibits its differentiation of male fetuses after gestational exposure. Ecotoxicol Environ Saf. 2021 Oct 30;228:112942. [Content Brief]

[6]. Di Renzo F, et al. Stage-dependent abnormalities induced by the fungicide triadimefon in the mouse. Reprod Toxicol. 2011 Feb;31(2):194-9. [Content Brief]

[7]. Xi J, et al. Suppressive effect of triadimefon, a triazole fungicide, on spatial learning and reference memory in rats. Behav Pharmacol. 2012 Dec;23(8):727-34. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4043 mL	17.0213 mL	34.0426 mL	85.1064 mL
	5 mM	0.6809 mL	3.4043 mL	6.8085 mL	17.0213 mL
	10 mM	0.3404 mL	1.7021 mL	3.4043 mL	8.5106 mL
	15 mM	0.2270 mL	1.1348 mL	2.2695 mL	5.6738 mL
	20 mM	0.1702 mL	0.8511 mL	1.7021 mL	4.2553 mL
	25 mM	0.1362 mL	0.6809 mL	1.3617 mL	3.4043 mL
	30 mM	0.1135 mL	0.5674 mL	1.1348 mL	2.8369 mL
	40 mM	0.0851 mL	0.4255 mL	0.8511 mL	2.1277 mL
	50 mM	0.0681 mL	0.3404 mL	0.6809 mL	1.7021 mL
	60 mM	0.0567 mL	0.2837 mL	0.5674 mL	1.4184 mL
	80 mM	0.0426 mL	0.2128 mL	0.4255 mL	1.0638 mL
	100 mM	0.0340 mL	0.1702 mL	0.3404 mL	0.8511 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Triadimefon

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Antifungal Compound Library

Endoplasmic Reticulum Stress Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Pesticide Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Environmental Pollutant Compound Library

Lactylation Compound Library

Alle Akt Isoform-spezifische Produkte anzeigen

Alle AMPK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Triadimefon Related Classifications

HY-123037 Related Classifications